McGuire, D.K., et al., Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial
Reddys and Apotex filed IPRs against the 462 patent, which were instituted
2 Since SLC25A39 protein is expressed in various tissues including the postnatal brain (see for details e.g.,: this may hint for a specific role of that carrier in mitochondrial activity of certain neuronal populations
Ozempic patients are also suffering from pancreatitis, gastroparesis, and vision loss, and they are filing lawsuits because of it
"These policy shifts not only validate our strategic direction but also demonstrate our alignment with both market needs and the future of healthcare," added Anthony Puopolo, M.D., President, LifeMD Affiliated P.C.s